At a glance
- Originator Allergan
- Developer AbbVie
- Class Antineoplastics; Retinoids
- Mechanism of Action Retinoic acid receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 09 Sep 1999 Profile reviewed but no significant changes made
- 11 Mar 1997 New profile